{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:55:50Z","timestamp":1791186950290,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05679-8","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T09:18:15Z","timestamp":1786094295000},"page":"4583-4596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["METTL3 promotes proliferation and invasion and inhibits ferroptosis in hepatocellular carcinoma by mediating m6A methylation modification of NUPR1"],"prefix":"10.1007","volume":"481","author":[{"given":"Yushan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"Suppl 1(Suppl 1","key":"5679_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB (2021) Epidemiology of hepatocellular carcinoma. Hepatology 73(Suppl 1(Suppl 1)):4\u201313","journal-title":"Hepatology"},{"key":"5679_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2147\/JHC.S450460","volume":"11","author":"P Chen","year":"2024","unstructured":"Chen P, Li Y, Dai Y, Wang Z, Zhou Y, Wang Y, Li G (2024) Advances in the pathogenesis of metabolic liver disease-related hepatocellular carcinoma. J Hepatocell Carcinoma 11:581\u2013594","journal-title":"J Hepatocell Carcinoma"},{"key":"5679_CR3","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429310703240823045808","volume":"17","author":"B Sensi","year":"2024","unstructured":"Sensi B, Angelico R, Toti L, Conte L, Coppola A, Tisone G, Manzia TM (2024) Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation. Curr Mol Pharmacol 17:e18761429310703","journal-title":"Curr Mol Pharmacol"},{"issue":"4","key":"5679_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C (2023) Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 20(4):203\u2013222","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"5679_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Deng B (2023) Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev 42(3):629\u2013652","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"5679_CR6","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.2174\/1570180820666230601113529","volume":"21","author":"Y Yuguang","year":"2024","unstructured":"Yuguang Y, Hui T, Cong M, Xin Z, Jiawen K, Yunqiang T (2024) Analysis of the safety and effectiveness of Lenvatinib + TACE-HAIC + PD-1 inhibitor for intermediate and advanced hepatocellular carcinoma. Lett Drug Des Discov 21(11):2035\u20132045","journal-title":"Lett Drug Des Discov"},{"issue":"1","key":"5679_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/0113892029308243240709073945","volume":"26","author":"G Indu Priya","year":"2025","unstructured":"Indu Priya G, Krishna Chaitanya A (2025) Integrative bioinformatics analysis for targeting hub genes in hepatocellular carcinoma treatment. Curr Genomics 26(1):48\u201380","journal-title":"Curr Genomics"},{"issue":"1","key":"5679_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/genes15010137","volume":"15","author":"S Zmorzynski","year":"2024","unstructured":"Zmorzynski S, Kimicka-Szajwaj A, Szajwaj A, Czerwik-Marcinkowska J, Wojcierowski J (2024) Genetic changes in mastocytes and their significance in mast cell tumor prognosis and treatment. Genes (Basel) 15(1):137","journal-title":"Genes (Basel)"},{"issue":"1","key":"5679_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An Y, Duan H (2022) The role of m6A RNA methylation in cancer metabolism. Mol Cancer 21(1):14","journal-title":"Mol Cancer"},{"issue":"1","key":"5679_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.curpro.2025.100001","volume":"22","author":"Z Wu","year":"2025","unstructured":"Wu Z, Shen N, Song P, Wang B, Li C (2025) SP1-mediated WTAP exacerbates the progression of colon adenocarcinoma by m6A methylation of KLK8. Curr Proteomics 22(1):100001","journal-title":"Curr Proteomics"},{"key":"5679_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.989637","volume":"16","author":"D Liu","year":"2022","unstructured":"Liu D, Fan B, Li J, Sun T, Ma J, Zhou X, Feng S (2022) N6-methyladenosine modification: a potential regulatory mechanism in spinal cord injury. Front Cell Neurosci 16:989637","journal-title":"Front Cell Neurosci"},{"issue":"13\u201314","key":"5679_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202200208","volume":"23","author":"Y Wei","year":"2023","unstructured":"Wei Y, Li Y, Lu C (2023) Exploring the role of m6A modification in cancer. Proteomics 23(13\u201314):e2200208","journal-title":"Proteomics"},{"key":"5679_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216658","volume":"587","author":"K Ao","year":"2024","unstructured":"Ao K, Yin M, Lyu X, Xiao Y, Chen X, Zhong S, Wen X, Yuan J, Ye M, Zhang J et al (2024) METTL3-mediated HSPA9 m6A modification promotes malignant transformation and inhibits cellular senescence by regulating exosomal mortalin protein in cervical cancer. Cancer Lett 587:216658","journal-title":"Cancer Lett"},{"issue":"1","key":"5679_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41419-023-06411-w","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, He Y, Li Z, Zhang N, Zhou C, He X, Xue D (2024) METTL3 facilitates renal cell carcinoma progression by PLOD2 m(6)A-methylation under prolonged hypoxia. Cell Death Dis 15(1):62","journal-title":"Cell Death Dis"},{"issue":"10","key":"5679_CR15","first-page":"745","volume":"39","author":"S Fu","year":"2024","unstructured":"Fu S, Sun D, Wang Z, Zhu P, Ding W, Huang J, Guo X, Yang Y, Gu F (2024) METTL3-mediated m(6)A modification of FMRP drives hepatocellular carcinoma progression and indicates poor prognosis. Cancer Biother Radiopharm 39(10):745\u2013754","journal-title":"Cancer Biother Radiopharm"},{"key":"5679_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156228","volume":"275","author":"D Pan","year":"2025","unstructured":"Pan D, Zhang H, Zhou J, He S, Yuan G (2025) METTL3\/IGF2BP2 stabilizes IQGAP3 via m6A modification to drive HCC metastasis through TGF-beta\/Smad signaling and EMT. Pathol Res Pract 275:156228","journal-title":"Pathol Res Pract"},{"issue":"1","key":"5679_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02132-6","volume":"23","author":"JX Shi","year":"2024","unstructured":"Shi JX, Zhang ZC, Yin HZ, Piao XJ, Liu CH, Liu QJ, Zhang JC, Zhou WX, Liu FC, Yang F et al (2024) RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy. Mol Cancer 23(1):213","journal-title":"Mol Cancer"},{"issue":"9","key":"5679_CR18","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.7150\/ijbs.96014","volume":"20","author":"X Zhu","year":"2024","unstructured":"Zhu X, Sha X, Zang Y, Ren Q, Zhang S, Ma D, Wang L, Yao J, Zhou X, Yu L et al (2024) Current progress of ferroptosis study in hepatocellular carcinoma. Int J Biol Sci 20(9):3621\u20133637","journal-title":"Int J Biol Sci"},{"issue":"1","key":"5679_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01213-z","volume":"8","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang Y, Wang Z, Yu L, Chen K, Xie Y, Liu Y, Liang W, Zheng Y, Zhan Y et al (2022) The interplay of transcriptional coregulator NUPR1 with SREBP1 promotes hepatocellular carcinoma progression via upregulation of lipogenesis. Cell Death Discov 8(1):431","journal-title":"Cell Death Discov"},{"issue":"1","key":"5679_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02554-3","volume":"20","author":"Y Zhan","year":"2022","unstructured":"Zhan Y, Zhang Z, Liu Y, Fang Y, Xie Y, Zheng Y, Li G, Liang L, Ding Y (2022) NUPR1 contributes to radiation resistance by maintaining ROS homeostasis via AhR\/CYP signal axis in hepatocellular carcinoma. BMC Med 20(1):365","journal-title":"BMC Med"},{"issue":"1","key":"5679_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00662-2","volume":"7","author":"C Huang","year":"2021","unstructured":"Huang C, Santofimia-Castano P, Liu X, Xia Y, Peng L, Gotorbe C, Neira JL, Tang D, Pouyssegur J, Iovanna J (2021) NUPR1 inhibitor ZZW-115 induces ferroptosis in a mitochondria-dependent manner. Cell Death Discov 7(1):269","journal-title":"Cell Death Discov"},{"issue":"1","key":"5679_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14291-w","volume":"25","author":"C Sun","year":"2025","unstructured":"Sun C, Sun X, Chen Y, Wu Y, Xiang C, Wu S (2025) Platycodin D-mediated METTL16 downregulation promotes docetaxel treatment of prostate cancer by regulating ferroptosis. BMC Cancer 25(1):1042","journal-title":"BMC Cancer"},{"issue":"2","key":"5679_CR23","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s10528-023-10423-8","volume":"62","author":"M Tan","year":"2024","unstructured":"Tan M, He Y, Yi J, Chen J, Guo Q, Liao N, Peng L (2024) WTAP mediates NUPR1 regulation of LCN2 through m(6)A modification to influence ferroptosis, thereby promoting breast cancer proliferation, migration and invasion. Biochem Genet 62(2):876\u2013891","journal-title":"Biochem Genet"},{"key":"5679_CR24","doi-asserted-by":"publisher","first-page":"155953","DOI":"10.1016\/j.metabol.2024.155953","volume":"157","author":"Y Sui","year":"2024","unstructured":"Sui Y, Geng X, Wang Z, Zhang J, Yang Y, Meng Z (2024) Targeting the regulation of iron homeostasis as a potential therapeutic strategy for nonalcoholic fatty liver disease. Metabolism 157:155953","journal-title":"Metabolism"},{"issue":"3","key":"5679_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188890","volume":"1878","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W (2023) GPX4: the hub of lipid oxidation, ferroptosis, disease and treatment. Biochim Biophys Acta Rev Cancer 1878(3):188890","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"7","key":"5679_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6989","volume":"13","author":"A Guan","year":"2024","unstructured":"Guan A, Wong JJ (2024) Targeting RNA modifications with pharmacological agents: new frontiers in cancer therapy. Cancer Med 13(7):e6989","journal-title":"Cancer Med"},{"issue":"11","key":"5679_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lddd.2025.100236","volume":"22","author":"D Xu","year":"2025","unstructured":"Xu D, Chen T, Ma X (2025) HS3ST2, regulated by METTL14 through m6A mechanisms, contributes to M1 macrophage polarization in chronic obstructive pulmonary disease. Lett Drug Des Discov 22(11):100236","journal-title":"Lett Drug Des Discov"},{"issue":"1","key":"5679_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13045-020-00951-w","volume":"13","author":"C Zeng","year":"2020","unstructured":"Zeng C, Huang W, Li Y, Weng H (2020) Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol 13(1):117","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5679_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-023-02638-9","volume":"42","author":"Y Sun","year":"2023","unstructured":"Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T, Zhu W, Zhang J (2023) METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J Exp Clin Cancer Res 42(1):65","journal-title":"J Exp Clin Cancer Res"},{"key":"5679_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110971","volume":"113","author":"CH Liu","year":"2024","unstructured":"Liu CH, Zhang JJ, Zhang QJ, Dong Y, Shi ZD, Hong SH, He HG, Wu W, Han CH, Hao L (2024) METTL3 regulates the proliferation, metastasis and EMT progression of bladder cancer through P3H4. Cell Signal 113:110971","journal-title":"Cell Signal"},{"issue":"11","key":"5679_CR31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41419-023-06287-w","volume":"14","author":"Y Sun","year":"2023","unstructured":"Sun Y, Gong W, Zhang S (2023) METTL3 promotes colorectal cancer progression through activating JAK1\/STAT3 signaling pathway. Cell Death Dis 14(11):765","journal-title":"Cell Death Dis"},{"issue":"5","key":"5679_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3892\/ijo.2024.5693","volume":"65","author":"H Zhang","year":"2024","unstructured":"Zhang H, Han B, Tian S, Gong Y, Liu L (2024) ZNF740 facilitates the malignant progression of hepatocellular carcinoma via the METTL3\/HIF-1A signaling axis. Int J Oncol 65(5):105","journal-title":"Int J Oncol"},{"issue":"1","key":"5679_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, Li B (2019) Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol 12(1):34","journal-title":"J Hematol Oncol"},{"issue":"1","key":"5679_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, Sun Y, Zeng F, Chen X, Deng G (2024) Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther 9(1):55","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"5679_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12072-023-10593-y","volume":"18","author":"Y Mo","year":"2024","unstructured":"Mo Y, Zou Z, Chen E (2024) Targeting ferroptosis in hepatocellular carcinoma. Hepatol Int 18(1):32\u201349","journal-title":"Hepatol Int"},{"key":"5679_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1252064","volume":"12","author":"Q Liu","year":"2024","unstructured":"Liu Q, Lv L, Cai X, Zhu J, Li J, Yang L, Xie X, Zhao C, Zhao H (2024) Correlation between RNA N6-methyladenosine and ferroptosis in cancer: current status and prospects. Front Cell Dev Biol 12:1252064","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"5679_CR37","doi-asserted-by":"publisher","DOI":"10.1515\/med-2023-0882","volume":"19","author":"P Zhang","year":"2024","unstructured":"Zhang P, Wang S, Chen Y, Yang Q, Zhou J, Zang W (2024) METTL3 attenuates ferroptosis sensitivity in lung cancer via modulating TFRC. Open Med 19(1):20230882","journal-title":"Open Med"},{"issue":"4","key":"5679_CR38","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.7150\/ijbs.100518","volume":"21","author":"Z Dai","year":"2025","unstructured":"Dai Z, Lin B, Qin M, Lin Y, Wang L, Liao K, Xie G, Wang F, Zhang J (2025) METTL3-mediated m6A modification of SLC7A11 enhances nasopharyngeal carcinoma radioresistance by inhibiting ferroptosis. Int J Biol Sci 21(4):1837\u20131851","journal-title":"Int J Biol Sci"},{"issue":"1","key":"5679_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41419-024-07317-x","volume":"16","author":"C Zhang","year":"2025","unstructured":"Zhang C, Yang T, Chen H, Ding X, Chen H, Liang Z, Zhao Y, Ma S, Liu X (2025) METTL3 inhibition promotes radiosensitivity in hepatocellular carcinoma through regulation of SLC7A11 expression. Cell Death Dis 16(1):9","journal-title":"Cell Death Dis"},{"issue":"7","key":"5679_CR40","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1136\/gutjnl-2019-319639","volume":"69","author":"Q Wang","year":"2020","unstructured":"Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, Jiang Z, Zhang Y, Xu G, Zhang J et al (2020) METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut 69(7):1193\u20131205","journal-title":"Gut"},{"issue":"9","key":"5679_CR41","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","volume":"82","author":"Z Ni","year":"2022","unstructured":"Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, Yin M, Cui C, Wang G, Yuan L et al (2022) JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA. Cancer Res 82(9):1789\u20131802","journal-title":"Cancer Res"},{"key":"5679_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-026-09527-0","author":"R Shu","year":"2026","unstructured":"Shu R, Cheng Q, Yu Z, Zhou H, Lin M, Shi M, Chen J, Chen J, Zhao M (2026) The METTL3-IGF2BP3 axis drives osteosarcoma progression by enhancing ID1 mRNA stability. BMC Musculoskelet Disord. https:\/\/doi.org\/10.1186\/s12891-026-09527-0","journal-title":"BMC Musculoskelet Disord"},{"key":"5679_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2020.04.024","volume":"486","author":"W Lan","year":"2020","unstructured":"Lan W, Santofimia-Castano P, Xia Y, Zhou Z, Huang C, Fraunhoffer N, Barea D, Cervello M, Giannitrapani L, Montalto G et al (2020) Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma. Cancer Lett 486:8\u201317","journal-title":"Cancer Lett"},{"issue":"1","key":"5679_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20904-2","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Song X, Kuang F, Zhang Q, Xie Y, Kang R, Kroemer G, Tang D (2021) NUPR1 is a critical repressor of ferroptosis. Nat Commun 12(1):647","journal-title":"Nat Commun"},{"issue":"7","key":"5679_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70519","volume":"29","author":"Y Fang","year":"2025","unstructured":"Fang Y, Chen H, Liu Y, Jiang K, Qian Y, Wei J, Fu D, Yang H, Dai S, Jin T et al (2025) NUPR1 promotes radioresistance in colorectal cancer cells by inhibiting ferroptosis. J Cell Mol Med 29(7):e70519","journal-title":"J Cell Mol Med"},{"issue":"13","key":"5679_CR46","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41388-024-02956-y","volume":"43","author":"Z Chen","year":"2024","unstructured":"Chen Z, Zhou J, Wu Y, Chen F, Li J, Tao L, Tian Y, Wang H, Li J, Li Z et al (2024) METTL3 promotes cellular senescence of colorectal cancer via modulation of CDKN2B transcription and mRNA stability. Oncogene 43(13):976\u2013991","journal-title":"Oncogene"},{"issue":"1","key":"5679_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13046-022-02581-1","volume":"42","author":"Y Xu","year":"2023","unstructured":"Xu Y, Song M, Hong Z, Chen W, Zhang Q, Zhou J, Yang C, He Z, Yu J, Peng X et al (2023) The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer. J Exp Clin Cancer Res 42(1):10","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"5679_CR48","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/1541-7786.MCR-24-0362","volume":"23","author":"W Chen","year":"2025","unstructured":"Chen W, Zhang J, Ma W, Liu N, Wu T (2025) METTL3-Mediated m6A modification regulates the polycomb repressive complex 1 components BMI1 and RNF2 in hepatocellular carcinoma cells. Mol Cancer Res 23(3):190\u2013201","journal-title":"Mol Cancer Res"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05679-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:45:00Z","timestamp":1791186300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05679-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5679"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05679-8","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was permitted by the Ethics Committee of Shanxi Province Cancer Hospital [Approval Number: KY2026139], and complied with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies were performed in compliance with the ARRIVE guidelines and the Basel Declaration. All animals received humane\u00a0care\u00a0according\u00a0to\u00a0the\u00a0National\u00a0Institutes\u00a0of\u00a0Health\u00a0(USA)\u00a0guidelines.","order":3,"name":"Ethics","label":"Research involving human and animal participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consents were obtained from all participants and all protocols were in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consents were obtained from all participants.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}